Specific 125I-radioimmunoassay for cholyglycine, a bile acid, in serum.

Miller, Philip; Weiss, Susan; Cornell, Martha; Dockery, Jeanne

doi:10.1093/clinchem/27.10.1698

Cited by 31 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To determine if the vitamin E deficiency state further altered liver function in children with chronic cholestasis, blood tests of hepatic injury and function were monitored before and at 6-to 12-month intervals during the course of vitamin E therapy. Fasting blood was obtained for analysis of serum cholylglycine (radioimmunoassay; CG, Abbott Laboratories, North Chicago, Ill.) (20), AST, ALT, alkaline phosphatase, total and direct bilirubin, albumin, total protein, cholesterol, triglycerides, phospholipids (15), prothrombin time and partial thromboplastin time. During this study (in 1982), the antibody used in the cholylglycine kit was changed by the manufacturer.…”

Section: Methodsmentioning

confidence: 99%

Correction of vitamin E deficiency in children with chronic cholestasis. II. Effect on gastrointestinal and hepatic function

et al. 1986

View full text Add to dashboard Cite

Although secondary vitamin E deficiency causes a reversible neurologic disorder in children with chronic cholestasis, the effect of this deficiency state on other organ systems is unknown. We studied the effects of vitamin E therapy on selected gastrointestinal and hepatic functions in five children with chronic cholestasis and well-documented biochemical and neurologic evidence of vitamin E deficiency. After 2 to 3 years of oral or parenteral vitamin E therapy, there was no improvement in fecal fat losses, severity of vitamin E malabsorption (as measured by an oral vitamin E tolerance test) or total serum fatty acid concentrations. Serial analyses of liver function blood tests demonstrated a marked decline in fasting serum cholylglycine concentrations during 18 to 31 months of vitamin E therapy, while other liver function tests showed no consistent changes. We conclude that vitamin E deficiency does not appear to alter intestinal absorption of fat or vitamin E; however, vitamin E deficiency may further impair already compromised hepatic function during pathologic conditions such as cholestasis.

show abstract

Section: Methodsmentioning

confidence: 99%

Correction of vitamin E deficiency in children with chronic cholestasis. II. Effect on gastrointestinal and hepatic function

et al. 1986

View full text Add to dashboard Cite

show abstract

“…Cholylglycine (CG), one of the main components of bile acid, is a highly sensitive and specific biomarker to diagnose liver abnormalities [1,2]. The normal metabolic pathway of CG is enterohepatic circulation [2,3].…”

Section: Introductionmentioning

confidence: 99%

Reusable optofluidic point-of-care testing platform with lyophilized specific antibody for fluorescence detection of cholylglycine in serum

Liu

Zhu³

et al. 2020

Microchim Acta

View full text Add to dashboard Cite

A reusable optofluidic point-of-care testing platform (OPOCT) was successfully constructed through integrating evanescent wave fluorescence technology into an all-fiber-based optofluidic system. The compact design of the OPOCT allows it to be portable and suitable for on-site sensitive determination of biomarkers in serum without complicated and costly procedures. The sensitivity of 90.9 pM for antibody determination is observed thanks to the high transmission efficiency of excitation light and fluorescence in the OPOCT. The affinity constant between cholylglycine (CG) and anti-CG antibody was quantified using this platform based on the proposed theory. Using the lyophilized fluorescence-labeled specific antibody and reusable fiber optic biosensor, the OPOCT is applied to the one-step sensitive determination of CG in serum, which eliminates the dearth associated with liquid reagent handling, disposable biosensors, and user intervention. A limit of detection of 0.025 μg/mL for CG is obtained, which is far more than adequate for meeting diagnostic requirements. The matrix effect of serum samples on the evanescent wave-based optofluidic biosensor can be effectively reduced by simple dilution of serum samples. The performance of the OPOCT also compared favorably with that of a commercial turbidimetric inhibition immunoassay through analyzing multiple serum samples. This platform is ready to expand to measure any other biomarker by using its specific antibody. The simplicity, sensitivity, cost-effectiveness, and robustness of the OPOCT enable the early diagnosis of disease and making a timely clinical decision.

show abstract

“…Cholyglycine (CG) is a circulating conjugated bile acid derived from cholic acid and glycine. Several reports show that serum CG levels are usually abnormal in liver diseases such as viral hepatitis, alcoholic liver disease, cirrhosis, and pediatric liver diseases . Currently, there are several techniques to estimate CG levels in serum including gas‐liquid chromatography , fluorescence polarization immunoassay , radioimmunoassay , and EMIT .…”

Section: Introductionmentioning

confidence: 99%

Glucose‐6‐phosphate dehydrogenase mutant D306C has a higher inhibition rate for enzyme multiplied immunoassay of cholyglycine

Qi¹,

Xiao²,

Zhang³

et al. 2019

Biotech and App Biochem

View full text Add to dashboard Cite

Glucose-6-phosphate dehydrogenase (G6PDH) has been used in enzyme multiplied immunoassay technique (EMIT) assays for detecting small molecule metabolites such as cholyglycine (CG). A key parameter for successful EMIT CG assay development is the inhibition rate of the G6PDH-CG conjugate, measured as the decrease in enzyme activity upon CG antibody binding. Several commonly used G6PDH cysteine mutants including A45C and K55C have been labeled with CG-maleimide derivative, but inhibition rates of are unsatisfactory. Herein, we investigated whether other mutation sites can achieve better inhibition rates. We generated eight cysteine mutants (K106C, Y155C, A201C, T258C, D306C, D375C, G426C, and D480C) of G6PDH, measured their inhibition rates, and evaluated the performance of the D306C mutant using EMIT CG assays. One of the eight mutants (D306C) displayed improved inhibition rate, whereas all others exhibited inhibition similar to or lower than that of A45C and K55C. The enhanced inhibition rate of D306C improved the EMIT CG assay calibration curve, using an Abbott c16000 automated biochemical analyzer, resulting in better repeatability, precision, and linearity than with K55C assays and a commercially available EMIT CG kit. The G6PDH mutant D306C has a higher inhibition rate in EMIT CG assays and improves assay performance.

show abstract

Specific 125I-radioimmunoassay for cholyglycine, a bile acid, in serum.

Cited by 31 publications

References 0 publications

Correction of vitamin E deficiency in children with chronic cholestasis. II. Effect on gastrointestinal and hepatic function

Correction of vitamin E deficiency in children with chronic cholestasis. II. Effect on gastrointestinal and hepatic function

Reusable optofluidic point-of-care testing platform with lyophilized specific antibody for fluorescence detection of cholylglycine in serum

Glucose‐6‐phosphate dehydrogenase mutant D306C has a higher inhibition rate for enzyme multiplied immunoassay of cholyglycine

Contact Info

Product

Resources

About